In order to test the targeting efficacy of CAPE-MotAb, we first examined the expression level of mortalin on the cell surface of various cancer cells by fluorescence-activated cell sorting (FACS) using a specific anti-mortalin antibody. Here, HSPA9 is linked to cancer.